Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC)

Background: FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve pts. with MPC, but carries an unfavorable adverse event (AE) profile.

Saved in:

Bibliographic Details
Published in:	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Vol. 16; no. 4; pp. S30 - S31
Main Authors:	Ozaka, Masato, Ishii, Hiroshi, Sato, Tosiya, Ueno, Makoto, Ikeda, Masafumi, Uesugi, Kazuhiro, Sata, Naohiro, Miyashita, Kouichirou, Mizuno, Nobumasa, Tsuji, Kunihiro, Okusaka, Takuji, Furuse, Junji
Format:	Journal Article
Language:	English
Published:	Philadelphia Elsevier B.V 01.08.2016 Elsevier Limited
Subjects:	Chemotherapy Confidence intervals Endocrinology & Metabolism Gastroenterology and Hepatology Metastasis Neutropenia Pancreatic cancer
ISSN:	1424-3903, 1424-3911
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!